Applying a Phase II Futility Study Design to Therapeutic Stroke Trials
Yuko Y. Palesch(Virginia Department of Health), Robert F. Woolson(Medical University of South Carolina)
Cited by 59
Related Papers
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
|The Lancet Neurology|2019|249
Circadian Variation in Ischemic Stroke Subtypes
|Stroke|1999|102
Use of antithrombotic drugs in the treatment of acute ischemic stroke
|Neurology|1989|74
An Overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Project
|Annals of Emergency Medicine|2012|49